Atarax
(Hydroxyzine)ApprovedSmall molecule
PfizerHydroxyzine is an antihistamine used to reduce itching from allergic skin reactions, calm anxiety and tension, and help patients relax before and after surgery. It works by blocking histamine in the body and reducing brain activity.[2] Atarax is currently approved and in use across 7 indications[4].[1]
Atarax is one of 150 small molecule programs targeting Eating Disorder. It is currently in Approved.
7
Indications
13
Total Trials
1
Active Trials
149
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
165 competitors in Anxiety
#DrugCompanyPhaseTrials
1Atarax
PfizerApproved
Valium
Akero TherapeuticsPhase 3
Duloxetine Hydrochloride
Eli LillyPhase 3
Chamomile
HHams Hamed Abdelrahman
Phase 3
Centanafadine
OtsukaPhase 3
Celexa
AbbViePreclinical
Spravato
WWim Janssens
Preclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Campral
FForest Laboratories
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation2 trials
Children1 trial
7 more indications
Hip Fracture1 trial
Eating Disorder1 trial
Pruritus1 trial
Hysterectomy1 trial
Driving1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
VISTARIL
NDA NDA011459
Jan 1, 1982
VISTARIL
NDA NDA011111
Jan 1, 1982
VISTARIL
NDA NDA011795
Jan 1, 1982
ATARAX
NDA NDA010485
Jan 1, 1982
ATARAX
NDA NDA010392
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Atarax drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Hydroxyzine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]